433P - High Beclin-1 expression predicts prolonged survival in locally advanced non-small cell lung cancer receiving docetaxel-platinum induction chemothe...

Date 18 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Anticancer agents
Non-Small-Cell Lung Cancer, Locally Advanced
Translational Research
Presenter Hee Yeon Lee
Citation Annals of Oncology (2016) 27 (suppl_9): ix136-ix138. 10.1093/annonc/mdw593
Authors H.Y. Lee1, J.H. Shin2, K. Lee3, J.K. Park4, S.W. Sung4, Y.S. Kim5, J.H. Kang6, J. Kim7
  • 1Internal Medicine, The Catholic University of Korea Incheon St. Mary's Hospital, 21431 - Incheon/KR
  • 2Pathology, St.Paul's Hospital, 02559 - Seoul/KR
  • 3Pathology, Seoul St. Mary's Hospital, of the Catholic University, 06591 - Seoul/KR
  • 4Thoracic And Cardiovascular Surgery, Seoul St. Mary's Hospital, of the Catholic University, 06591 - Seoul/KR
  • 5Department Of Radiation Oncology, Seoul St. Mary's Hospital, of the Catholic University, 137-701 - Seoul/KR
  • 6Department Of Medical Oncology, Seoul St. Mary's Hospital, of the Catholic University, 137-701 - Seoul/KR
  • 7Bioscience, Seoul St. Mary's Hospital, of the Catholic University, 06591 - Seoul/KR

Abstract

Background

The outcome of local treatment for advanced non–small-cell lung cancer (NSCLC) still remains poor, with therapies such as induction chemotherapy (IC) yielding conflicting results. This study aimed to assess the clinocopathological and prognostic significance of ERCC1, beclin-1, and GRP78 in patients with locally advanced NSCLC receiving docetaxel-platinum IC, along with the efficacy and safety of the treatment.

Methods

We reviewed the medical records of 31 NSCLC patients treated with docetaxel-platinum IC, and performed immunohistochemical staining of ERCC1, beclin-1, and GRP78.

Results

Response rate was 67.8% with 10.7 months of median relapse-free survival (RFS) (95% CI, 5.5–15.8) and 23.1 months of overall survival (OS) (95% CI 15.1–31), and no treatment-related death was reported. High expression of ERCC1, beclin-1, and GRP78 was identified in 21 patients (67.7%), 27 patients (87.1%), and 21 patients (67.7%), respectively. Expression of ERCC1, beclin-1 and GRP78 did not show statistical significance in RFS, whereas in OS, patients with high expression of beclin-1 showed longer OS (7.6 vs. 23.2 months; log rank p = 0.024). In multivariate analysis, poor performance status (p = 0.021), poorly differentiated histology (p 

Conclusions

Our findings have shown that docetaxel-platinum IC is a safe and effective treatment option and beclin-1 expression is an independent favorable prognostic marker in locally advanced NSCLC.

Clinical trial indentification

Legal entity responsible for the study

N/A

Funding

N/A

Disclosure

All authors have declared no conflicts of interest.